Author: Younossi, Zobair M.; Stepanova, Maria; Lam, Brian; Cable, Rebecca; Felix, Sean; Jeffers, Thomas; Younossi, Elena; Pham, Huong; Srishord, Manirath; Austin, Patrick; Estep, Michael; Terra, Kathy; Escheik, Carey; de Avila, Leyla; Golabi, Pegah; Kolacevski, Andrej; Racila, Andrei; Henry, Linda; Gerber, Lynn
Title: Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVIDâ€19 Infection Cord-id: o1aatvy4 Document date: 2021_8_24
ID: o1aatvy4
Snippet: The impact of the coronavirus disease 2019 (COVIDâ€19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resource use among patients with NAFLD admitted with COVIDâ€19 by using electronic medical records data for adult patients with COVIDâ€19 hospitalized in a multihospital health system who were discharged between March and December 2020. NAFLD was diagno
Document: The impact of the coronavirus disease 2019 (COVIDâ€19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resource use among patients with NAFLD admitted with COVIDâ€19 by using electronic medical records data for adult patients with COVIDâ€19 hospitalized in a multihospital health system who were discharged between March and December 2020. NAFLD was diagnosed by imaging or liver biopsy without other liver diseases. Charlson’s comorbidity index (CCI) and Elixhauser comorbidity index (ECI) scores were calculated. In the study sample, among the 4,835 patients hospitalized for COVIDâ€19, 553 had NAFLD (age: 55 ± 16 years, 51% male, 17% White, 11% Black, 58% Hispanic, 8% Asian, 5% from congregated living, 58% obese, 15% morbid obesity [body mass index ≥ 40], 51% type 2 diabetes, 63% hypertension, mean [SD] baseline CCI of 3.9 [3.2], and baseline ECI of 13.4 [11.3]). On admission, patients with NAFLD had more respiratory symptoms, higher body temperature and heart rate, higher alanine aminotransferase and aspartate aminotransferase than nonâ€NAFLD controls (n = 2,736; P < 0.05). Of the patients with NAFLD infected with COVIDâ€19, 3.9% experienced acute liver injury. The NAFLD group had significantly longer length of stay, intensive care unit use, and mechanical ventilation, with a crude inpatient mortality rate of 11%. In multivariate analysis, independent predictors of inpatient mortality among patients with NAFLD infected with COVIDâ€19 were older age, morbid obesity, ECI score ≥ 11, higher Fibrosisâ€4 Index (FIBâ€4) score, and oxygen saturation <90% (all P < 0.05), but not sex, race/ethnicity, or any individual comorbidity (all P > 0.05). Conclusion: Patients with NAFLD infected with COVIDâ€19 tend to be sicker on admission and require more hospital resource use. Independent predictors of mortality included higher FIBâ€4 and multimorbidity scores, morbid obesity, older age, and hypoxemia on admission.
Search related documents:
Co phrase search for related documents- abdominal imaging and acute liver: 1, 2, 3, 4
- abdominal imaging and acute liver injury: 1
- absolute value and acute infection: 1, 2, 3, 4
- absolute value and acute liver: 1
- absolute value and acute myocardial: 1
- absolute value and acute myocardial infarction: 1
- acute infection and admission blood cell count: 1, 2, 3
- acute infection and admission date: 1, 2, 3
- acute liver and admission blood cell count: 1
- acute liver injury and admission blood cell count: 1
Co phrase search for related documents, hyperlinks ordered by date